Načítá se...

Thrombin Mutant W215A/E217A Treatment Improves Neurological Outcome and Reduces Cerebral Infarct Size in a Mouse Model of Ischemic Stroke

BACKGROUND AND PURPOSE: Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator (tPA) is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke with activated protein C (APC) improves outcomes; however, APC also has bleedi...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Berny-Lang, Michelle A., Hurst, Sawan, Tucker, Erik I., Pelc, Leslie A., Wang, Ruikang K., Hurn, Patricia D., Di Cera, Enrico, McCarty, Owen J.T., Gruber, András
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3115697/
https://ncbi.nlm.nih.gov/pubmed/21512172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.110.603811
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!